Bruker Advances Functional Proteomics 2.0 with timsOmniTM Mass Spectrometry Proteoform Analysis for Deeper Insights into Disease Biology
MWN-AI** Summary
Bruker Corporation has unveiled improvements to its timsOmni™ mass spectrometry platform aimed at advancing Functional Proteomics 2.0, which provides researchers with deeper insights into disease biology. The new capabilities enhance the characterization of proteoforms and post-translational modifications (PTMs), moving beyond traditional protein identification to focus on biologically significant protein variants.
At the core of these advancements is the integration of novel timsOmni workflows that utilize ultra-sensitive trapped eXd molecular fragmentation, allowing for greater specificity in analyzing complex samples. This innovation not only improves the identification of glycoproteins but also supports the discovery of PTMs relevant to various diseases. The recently updated Bruker ProteoScape™, GlycoScape™, and OmniScape™ software facilitate database-independent PTM discovery and offer high-confidence annotation of critical PTMs, enhancing researchers' ability to differentiate between proteoform variants that play pivotal roles in signaling pathways and therapeutic responses.
The release of the OmniWave™ algorithm in OmniScape 2026b further bolsters these capabilities, enabling top-down peptide sequencing, which is crucial in biotherapeutics research for verifying sequences and identifying modifications that could influence drug efficacy and side effects. Bruker's approach is particularly beneficial in the context of drug development, where understanding the structural nuances of therapeutic antibodies and their glycan distributions is vital.
Additionally, the introduction of AI-enhanced de novo peptide sequencing in ProteoScape 2026b allows researchers to discover peptide variants in metaproteomics and immunopeptidomics, addressing the need for insights into molecular diversity that standard databases may overlook. Bruker's innovative tools are set to propel research forward, offering new pathways for understanding disease mechanisms and enhancing drug discovery efforts.
MWN-AI** Analysis
Bruker Corporation’s recent advancements in proteomics, specifically with their timsOmni™ Mass Spectrometry platform, present significant investment opportunities for stakeholders interested in biotech and precision medicine. The launch of Functional Proteomics 2.0 workflows aimed at enhancing disease biology insights can solidify Bruker’s standing in the competitive landscape of drug discovery and development.
The timsOmni™ mass spectrometry technology's capacity for ultra-sensitive, deep proteoform analysis is poised to revolutionize the identification of complex post-translational modifications (PTMs) and provide a more granular understanding of pathophysiological processes. This advancement not only enhances academic research capabilities, but also offers potential for partnerships with pharmaceutical companies looking to fine-tune therapeutic strategies. Investors should note the implications of Bruker's integration of AI-enhanced sequencing tools in the ProteoScape™ software, which broadens the scope of applications to include metaproteomics and immunopeptidomics. With the growing focus on precision medicine, Bruker's innovative approaches could attract increased funding and collaboration from entities focused on personalized treatment options.
Moreover, the emphasis on confident proteoform characterization and glyco-heterogeneity analysis addresses unmet needs in therapeutic antibody development and biologics. As drug developers become more reliant on comprehensive biomarker identification, Bruker's capabilities position them favorably for sustained growth.
Despite potential volatility based on market reactions to technology adoption, Bruker’s strategic thrusts into AI, deep proteomics, and transformative workflows suggest a robust growth trajectory. Investors may consider accumulating shares in anticipation of wider applications in clinical diagnostics and therapeutic advancements, particularly as biopharmaceuticals continue to trend towards more targeted therapies backed by science-driven insights. Monitoring Bruker’s engagements with academia and industry will provide further clarity on its growth prospects in the evolving landscape of life sciences.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Novel timsOmni™ workflows enable deeper functional characterization of proteoforms and PTMs, leveraging multi-stage, ultra-sensitive trapped eXd molecular fragmentation
- Bruker ProteoScape™ expands AI?enhanced de novo peptide sequencing for complex samples from metaproteomics to immunopeptidomics
- timsOmni provides a powerful new ‘lamp post’ for illuminating many complex molecular, pathway and mechanism of action dark areas in drug discovery and development
Bruker Corporation (Nasdaq: BRKR) today announced new advancements to enable Functional Proteomics 2.0 workflows on the timsOmni™ mass spectrometer to enable disease researchers to move beyond canonical protein lists toward biologically or pathologically functional proteoforms and PTM-resolved peptide variants. New releases in Bruker ProteoScape ™, OmniScape ™, and GlycoScape ™ software now support database-independent PTM discovery, confident proteoform characterization, and eXd-enabled glycoproteomics for deeper biological, disease and drug discovery insights.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223057286/en/
Annotated timsOmni™ glycopeptide eXd spectrum from GlycoScape™ highlighting both glycan fragment ions as well as peptide fragment ions
Similarly, the now enabled timsOmni deep proteoform methods are equally powerful in interrogating drug targets, as well as biologics, including therapeutic antibodies, ADCs, multispecifics, and their PTM distributions and glyco-heterogeneity.
Confident proteoform characterization and eXd-enabled glycoproteomics on timsOmni
The latest version OmniScape™ 2026b strengthens timsOmni proteoform workflows by integrating the novel OmniWave™ algorithm, which enables top-down sequencing and proteoform identification at scale with high-confidence annotation of critical PTMs that drive disease signaling. Researchers can now move beyond protein group read-outs to proteoform-centric mechanisms, e.g., distinguishing signaling relevant protein variants that indicate disease states or treatment response. In biotherapeutics research, OmniScape supports verification of expected sequences and non-canonical modifications and can flag sequence variants or heterogeneity that may affect side effects or efficacy.
Bruker is greatly enhancing glycoproteomics with support for trapped electron?based dissociation (eXd) data in GlycoScape software, enabling confident glycopeptide characterization while preserving fragile glycan structures and supporting localization and topology insights. GlycoScape also provides interactive visualization of eXd fragment ions within annotated MS/MS spectra to simplify the validation of results.
“The timsOmni gives scientists access to eXd-enabled fragmentation that can resolve complex PTMs and proteoforms with outstanding fidelity,” said Professor Yehia Mechref, Director of the Texas Tech University Center for Biotechnology & Genomics. “The new software capabilities—especially eXd N-glycopeptide analysis and improved top-down workflows—support deeper understanding of disease biology and provide new avenues for target discovery and translational research.”
Bruker ProteoScape™ adds AI?enhanced de novo peptide sequencing for database?independent discovery in metaproteomics and immunopeptidomics
Bruker is introducing a new de novo peptide sequencing workflow in Bruker ProteoScape v2026b software that pairs an AI?enhanced scoring model—trained on more than seven million MS/MS spectra—with a proven dynamic?programming foundation to deliver accurate de novo sequences from high?resolution timsTOF data. This supports the demand for database?independent proteomics, enabling discovery of peptide variants across complex samples in applications such as metaproteomics and immunopeptidomics, including neoantigen research in immuno-oncology.
“Researchers are increasingly studying biological systems where reference databases alone do not capture the true molecular diversity,” said Bin Ma, founder of Rapid Novor Inc. “Our collaboration with Bruker has enabled Novor.AI to take advantage of large, high-quality timsTOF datasets and combine them with our AI model to deliver the speed, confidence, and precision needed for next-generation de novo peptide sequencing applications.”
About Bruker Corporation – Leader of the Post-Genomic Era
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in specialty diagnostics, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20260223057286/en/
Investor Contact:
Joe Kostka
Director - Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Media Contact:
Nora Williams
Marketing Director
Bruker Daltonics
T: +44 24 76855225
E: pr@bruker.com
FAQ**
How does Bruker Corporation BRKR plan to leverage the new advancements in the timsOmni™ mass spectrometer to enhance its competitive position in the proteomics market?
What specific revenue projections does Bruker Corporation BRKR anticipate from the introduction of its AI-enhanced de novo peptide sequencing capabilities?
In what ways does Bruker Corporation BRKR intend to integrate the new OmniWave™ algorithm into its existing product offerings to attract more researchers?
How does Bruker Corporation BRKR view the potential for its glycoproteomics advancements to positively impact its market share in the biotherapeutics sector?
**MWN-AI FAQ is based on asking OpenAI questions about Bruker Corporation (NASDAQ: BRKR).
NASDAQ: BRKR
BRKR Trading
-3.72% G/L:
$37.425 Last:
346,982 Volume:
$37.78 Open:
